Piperacillin/tazobactam (Tazocin) is indicated for the treatment of the following systemic and/or local bacterial infections caused by gram-positive and gram-negative aerobic and anaerobic organisms susceptible to piperacillin/tazobactam or piperacillin: Adults: Lower respiratory tract infections; Urinary tract infections; Intra-abdominal infections; Skin and skin structure infections; Bacterial septicemia; Gynecological infections, including post-partum endometritis and pelvic inflammatory disease (PID); Febrile neutropenic infections. Combination treatment with an aminoglycoside is recommended; Bone and joint infections; Polymicrobial infections (gram-positive/gram-negative aerobes and anaerobes).
Children (2 years of age or older): Febrile neutropenic infections. Combination treatment with an aminoglycoside is recommended; Intra-abdominal infections.
In serious infections, empiric therapy with piperacillin/tazobactam may be initiated before susceptibility test results are available.
Note: For associated bacteremia due to extended-beta-lactamase (ESBL) producing organisms, see Pharmacology: Pharmacodynamics under Actions.

Piperacillin/tazobactam (Tazocin) must be given by slow intravenous infusion (e.g., over 20-30 minutes).
Duration of Therapy: The duration of therapy should be guided by the severity of the infection and the patient’s clinical and bacteriological progress.
Adults and Children Aged 12 Years and Older: In general, the recommended total daily dosage is 12 g of piperacillin/1.5 g of tazobactam given in divided doses every 6 or 8 hours. Doses as high as 18 g of piperacillin/2.25 g of tazobactam per day in divided doses can be used in severe infections.
Pediatric Neutropenia: Febrile neutropenic patients in combination with an aminoglycoside: For children with normal renal function and weighing less than 50 kg, the dose should be adjusted to 80 mg of piperacillin/10 mg of tazobactam per kilogram of body weight every 6 hours, in combination with the appropriate dose of an aminoglycoside.
For children weighing over 50 kg, follow the adult dosing, in combination with the appropriate dose of an aminoglycoside.
Pediatric Intra-Abdominal Infection: For children aged 2 to 12 years, weighing up to 40 kg, and with normal renal function, the recommended dose is 100 mg piperacillin/12.5 mg tazobactam per kilogram of body weight every 8 hours.
For children aged 2 to 12 years, weighing over 40 kg, and with normal renal function, follow the adult dosing guidance. Therapy is recommended for a minimum of 5 days and a maximum of 14 days, considering that dose administration should continue at least 48 hours after the resolution of clinical signs and symptoms.
Use in Patients with Renal Impairment:In patients with renal impairment or in hemodialysis patients, intravenous dosages and administration intervals should be adjusted to the degree of renal function impairment as follows. (See Table 5.)

For patients on hemodialysis, one additional dose of piperacillin/tazobactam 2 g/0.25 g should be administered following each dialysis period, because hemodialysis removes 30%-50% of piperacillin in 4 hours.
Use in Patients with Hepatic Impairment: No dosage adjustment is necessary in patients with hepatic impairment.
Co-administration of Piperacillin/Tazobactam with Aminoglycosides: Due to the in vitro inactivation of the aminoglycoside by β-lactam antibiotics, piperacillin/tazobactam and the aminoglycoside are recommended for separate administration. Piperacillin/tazobactam and the aminoglycoside should be reconstituted and diluted separately when concomitant therapy with aminoglycosides is indicated (see Incompatibilities under Cautions for Usage).
In circumstances where co-administration is preferred, piperacillin/tazobactam containing EDTA supplied in vials is compatible for simultaneous co-administration via Y-site infusion only with the following aminoglycosides under the following conditions: See Table 6.

Compatibility of piperacillin/tazobactam with other aminoglycosides has not been established. Only the concentration and diluents for amikacin and gentamicin with the dosages of piperacillin/tazobactam listed in the table previously have been established as compatible for co-administration via Y-site infusion. Simultaneous co-administration via Y-site infusion in any manner other than listed previously may result in inactivation of the aminoglycoside by piperacillin/tazobactam.
Geriatric Population: Patients over 65 years are not at an increased risk of developing adverse effects solely because of age. However, dosage should be adjusted in the presence of renal insufficiency.

Overdosage